The short version of bremelanotide fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-02 and is reviewed periodically as new material appears.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Free base; the drug product is formulated as an acetate salt |
| Molar mass | About 1025 g/mol | Calculated for the free base |
| Appearance | White to off-white lyophilized powder | Typical form of research-grade material |
| CAS Registry Number | 189691-06-3 | Common listing for the free base |
| Typical storage | -20 °C, desiccated, protected from light | Repeated freeze-thaw cycles are best avoided |
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Whether the behavioral effect originates centrally, peripherally, or through both remains an active question. Animal experiments using receptor antagonists and site-specific injections point toward hypothalamic melanocortin circuits as a key locus, but translating those findings to humans is not straightforward. Blood pressure changes observed in trials suggest a vascular component that may be peripherally mediated. The relationship between receptor occupancy and reported effect has not been mapped in humans, and no validated biomarker predicts response. This gap makes it difficult to explain individual variability on pharmacological grounds alone.
Bremelanotide acts as an agonist at melanocortin receptors, a family of five G-protein-coupled receptors labeled MC1 through MC5. Binding studies indicate activity at several of these subtypes rather than strict selectivity for one. Signalling proceeds mainly through Gs-mediated activation of adenylyl cyclase, raising intracellular cyclic AMP. The MC4 receptor, expressed in hypothalamic and limbic circuits, is widely regarded as the subtype most relevant to sexual response. Because the molecule is not subtype-selective, effects at other melanocortin receptors are expected and are used to explain some observed side effects.
Dryer, acquired from the Giants in 1972, also made the Pro Bowl once, and set an NFL record with 2 safeties in one game against the Packers. Jones made the 1978 Pro Bowl team. The line was documented in NFL Network's A Football Life, and was narrated by Josh Charles.
The role of vitamin A in the visual cycle is specifically related to the retinal compound. Retinol is converted by the enzyme RPE65 within the retinal pigment epithelium into 11-cis-retinal. Within the eye, 11-cis-retinal is bound to the protein opsin to form rhodopsin in rod cells and iodopsin in cone cells. As light enters the eye, the 11-cis-retinal is isomerized to the all-trans form. The all-trans-retinal dissociates from the opsin in a series of steps called photo-bleaching. This isomerization induces a nervous signal along the optic nerve to the visual center of the brain. After separating from opsin, the all-trans-retinal is recycled and converted back to the 11-cis-retinal form by a series of enzymatic reactions, which then completes the cycle by binding to opsin to reform rhodopsin in the retina. In addition, some of the all-trans-retinal may be converted to all-trans-retinol form and then transported with an interphotoreceptor retinol-binding protein to the retinal pigmented epithelial cells. Further esterification into all-trans-retinyl esters allow for storage of all-trans-retinol within the pigment epithelial cells to be reused when needed. It is for this reason that a deficiency in vitamin A will inhibit the reformation of rhodopsin, and will lead to one of the first symptoms, night blindness.
=== Russell indices in Japan === Russell/Nomura equity indices for Japan (calculated with Nomura Securities Co., Ltd.) offer free-float adjusted broad market or style benchmarks for investors in that country.
Note that the elasticity of coiled springs comes from shear modulus, not Young's modulus. When a spring is stretched, its wire's length doesn't change, but its shape does. This is why only the shear modulus of elasticity is involved in the stretching of a spring.
Sources: en.wikipedia.org
=== Lutzner cells === Lutzner cells are bigger than normal lymphocytes and contain extensive folding in their membrane. They are described at being cerebriform in shape, and can be diploid or tetraploid. It also contains a large nucleus with a minimum cytoplasm. Lutzner cells are more predominant in Mycosis Fungoides, but are also found in Sézary Syndrome.
The Gibbs phase rule states that, under most thermodynamic conditions (fixed temperature, pressure, chemical potential, and other intensive thermodynamic properties), for each chemical species, only one phase is thermodynamically stable (i.e. have the lowest Gibbs free energy per volume), except on certain boundaries, such as the coexistence of ice and water right at the freezing point. In particular, since each crystal morph is a phase of matter, this implies that under normal circumstances, there exists only a single crystal morph at thermodynamic equilibrium. However, some phases may be kinetically stable, even if not energetically so. Disappearing polymorphs occur when there are two morphs of a substance, and one morph has lower Gibbs free energy, but is kinetically slower to form. Thus, when the crystal is first formed, the kinetically faster morph occurs first. Eventually, by accident or catalysis, the other morph occurs, which can then serve as seed crystal. More abstractly stated, disappearing polymorphs are morphs that are kinetically stable but not thermodynamically stable.
The precise reason why there are only four nucleotides is debated, but there are several unused possibilities. Furthermore, adenine is not the most stable choice for base pairing: in Cyanophage S-2L, diaminopurine (DAP) is used instead of adenine. Diaminopurine basepairs perfectly with thymine as it is identical to adenine but has an amine group at position 2 forming 3 intramolecular hydrogen bonds, eliminating the major difference between the two types of basepairs (weak A-T vs strong C-G). This improved stability affects protein-binding interactions that rely on those differences. Other combination include:
7-OH-MIT, like mitragynine, appears to be a mixed opioid receptor agonist/antagonist, with recent research indicating that it acts as a partial agonist at μ-opioid receptors and as a competitive antagonist at δ- and κ-opioid receptors. Both 7-OH-MIT and mitragynine do not appear to activate the β-arrestin pathway, distinguishing it from traditional opiate and opioid chemicals. Cross-tolerance to morphine was evident in mice rendered tolerant to 7-OH-MIT and vice versa. Naloxone-induced withdrawal signs were elicited equally in mice consistently dosed with 7-OH-MIT or morphine.
Peukert wrote: "Eclectic as regards ideas, but up to date in its attitude to technology, National Socialism laid claims to offer a "conclusive" new answer to the challenges and discomforts of the modern age". Peukert wrote that: "The much heralded Volksgemeinschaft of the National Socialists in no way abolished the real contradictions of a modern industrial society; rather these were inadvertently aggravated by the use of highly modern industrial and propaganda techniques for achieving war readiness. In fact, the long-term characteristics of a modern industrial society, which had been interrupted by the world economic crisis, continued to run their course". Reflecting the influence of functionalist historians like Martin Broszat and Hans Mommsen, Peukert wrote the inability to achieve the idealized volksgemeinschaft of their dreams left the National Socialists increasingly frustrated and led them to lash out against groups considered to be enemies of the volksgemeinschaft as a way of compensation. Peukert argued that for the National Socialists "it was more important to travel hopefully than to arrive", as for the Nazis had no solutions to the problems of classical modernity other than a creating a sense of movement towards the vague goal of the utopian society that was to be the volksgemeinschaft. Peukert wrote the "violent answers" of the Nazis to the "contradictions of modernity" were not the basis of a successful social order, and as such the dynamism of the Nazi movement was primarily negative and the "movement" had a strong self-destructive streak.
Sources: en.wikipedia.org
PT-141 is a research code for bremelanotide, a cyclic peptide that activates melanocortin receptors. It was developed for sexual dysfunction and later approved under a brand name as a subcutaneous injection. The same code is widely used by suppliers selling non-pharmaceutical material.
Both are synthetic melanocortin agonists and share a similar peptide backbone, but they are distinct molecules with different receptor profiles. Melanotan II was never approved as a medicine, whereas bremelanotide was. Findings about one compound should not be transferred to the other without direct evidence.
It is typically distributed as a lyophilized powder in sealed vials, sometimes with a separate solvent. Purity statements usually originate from the supplier rather than an independent laboratory. Storage recommendations vary between vendors, which makes comparison across sources difficult.
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.